Literature DB >> 22502902

Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.

Caroline Korves1, Adi Eldar-Lissai, Joshua McHale, Marie-Hélène Lafeuille, Siew Hwa Ong, Mei Sheng Duh.   

Abstract

BACKGROUND: Despite advances in its management and the identification of preventable risk factors, heart failure (HF) is a growing health problem in the US. The objective of this study was to describe treatment patterns, medical resource utilization and costs following hospitalization for chronic HF for patients stratified by age.
METHODS: Patients with at least one hospitalization with chronic HF were identified in a US commercial insurance claims database from 2004-2008. Patients were followed from the 1st day of chronic HF hospitalization (index hospitalization) until disenrollment or end of data availability. Inpatient, outpatient and prescription drug utilization rates were calculated per person per month (PPPM). Costs included payments made by insurers and, where available, patient out-of-pocket payments and sick-leave costs were also calculated. Utilization rates and costs were stratified by patient age.
RESULTS: There were 7814 patients included in the study. Index hospitalization was the most resource intensive and expensive ($31,023 age <65, $12,426 age ≥ 65). The rate of outpatient visits was the highest within 3 months following index hospitalization (3.6/PPPM age <65, 4.1/PPPM age ≥ 65). For the older age group, rate of re-hospitalizations was highest (0.06/PPPM) within 3-6 months following index hospitalization, while the younger group had its highest rate (0.08/PPPM) during the first 3 months following index hospitalization. Prescription dispensing rates were similar between age groups; average reimbursement PPPM for cardiovascular drugs did not exceed $92 (age <65) and $221 (age ≥ 65), which represents less than 3% of hospitalization costs for both groups.
CONCLUSIONS: Treating chronic HF patients is resource intensive. The greatest burden occurs within 6 months after index hospitalization for both age groups; patients continue to be burdened after hospitalization by high inpatient and outpatient visit rates. Outpatient cardiovascular drug costs account for a small proportion of total healthcare costs.

Entities:  

Mesh:

Year:  2012        PMID: 22502902     DOI: 10.3111/13696998.2012.685136

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  8 in total

1.  Systematic review of economic burden of heart failure.

Authors:  Asrul Akmal Shafie; Yui Ping Tan; Chin Hui Ng
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

2.  Heart Failure Hospitalization by Race/Ethnicity, Gender and Age in California: Implications for Prevention.

Authors:  Baqar A Husaini; Robert S Levine; Keith C Norris; Van Cain; Mohsen Bazargan; Majaz Moonis
Journal:  Ethn Dis       Date:  2016-07-21       Impact factor: 1.847

3.  The association between heart failure hospitalization and self-reported domains of health.

Authors:  Gregory A Nichols; Jacqueline Pesa; Daniel S Sapp; Aarti Patel
Journal:  Qual Life Res       Date:  2019-11-28       Impact factor: 4.147

4.  Improved medical expenditure and survival with integration of traditional Chinese medicine treatment in patients with heart failure: A nationwide population-based cohort study.

Authors:  Ming-Yen Tsai; Wen-Long Hu; Jen-Huai Chiang; Yu-Chuen Huang; Shih-Yu Chen; Yu-Chiang Hung; Yung-Hsiang Chen
Journal:  Oncotarget       Date:  2017-08-08

5.  Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial.

Authors:  Djawid Hashemi; Ludwig Dettmann; Tobias D Trippel; Volker Holzendorf; Johannes Petutschnigg; Rolf Wachter; Gerd Hasenfuß; Burkert Pieske; Antonia Zapf; Frank Edelmann
Journal:  ESC Heart Fail       Date:  2020-01-27

6.  National Trends in Hospitalization for Ambulatory Care Sensitive Conditions among Korean Adults between 2008 and 2019.

Authors:  Hyeki Park; Mi Jung Son; Da Won Jung; Hyejin Lee; Jin Yong Lee
Journal:  Yonsei Med J       Date:  2022-10       Impact factor: 3.052

7.  Analysis of hospitalization expenditures and influencing factors for inpatients with coronary heart disease in a tier-3 hospital in Xi'an, China: A retrospective study.

Authors:  Jing-Mei Ding; Xian-Zhi Zhang; Xue-Jun Hu; Huo-Liang Chen; Min Yu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.

Authors:  Ewa A Jankowska; Bridget-Anne Kirwan; Mikhail Kosiborod; Javed Butler; Stefan D Anker; Theresa McDonagh; Maria Dorobantu; Jarosław Drozdz; Gerasimos Filippatos; Andre Keren; Irakli Khintibidze; Hans Kragten; Felipe A Martinez; Marco Metra; Davor Milicic; José C Nicolau; Marcus Ohlsson; Alexander Parkhomenko; Domingo A Pascual-Figal; Frank Ruschitzka; David Sim; Hadi Skouri; Peter van der Meer; Basil S Lewis; Josep Comin-Colet; Stephan von Haehling; Alain Cohen-Solal; Nicolas Danchin; Wolfram Doehner; Henry J Dargie; Michael Motro; Tim Friede; Vincent Fabien; Fabio Dorigotti; Stuart Pocock; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2021-06-03       Impact factor: 29.983

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.